Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

REFERENCES

• Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403–2413
   PubMed Web of Science ®Google Scholar
• Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Proceedings of the American Society of Clinical Oncology. Orlando, FL. 2005
   Google Scholar
• Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. ECCO 2005; 13, Paris
   Google Scholar
• Reni M., Pasetto L., Aprile G., Cordio S., Bonetto E., Dell'Oro S., et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br. J. Cancer 2006; 94(6)785–791
   PubMed Web of Science ®Google Scholar
• Font A., Sanchez J. M., Rosell R., Taron M., Martinez E., Guillot M., et al. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung. Cancer 2002; 37(2)213–218
   PubMed Web of Science ®Google Scholar
• Goldwasser F., Shimizu T., Jackman J., Hoki Y., O'Connor P. M., Kohn K. W., et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996; 56(19)4430–4437
   PubMed Web of Science ®Google Scholar
• Burtness B., Sipples R., Mirto G., Thomas L., Rahman Z., Kloss R. A., et al. Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings. 2004; 22: 14S, 4116, (July 15 Supplement))
   Google Scholar
• Ko A. H., Hwang J., Venook A. P., Abbruzzese J. L., Bergsland E. K., Tempero M. A. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br. J. Cancer 2005; 93(2)195–199
   PubMed Web of Science ®Google Scholar
• Ko A. H., Dito E., Schillinger B., Venook A. P., Bergsland E. K., Tempero M. A., Phase I I. study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J. Clin. Oncol. 2006; 24(3)379–385
   PubMed Web of Science ®Google Scholar
• Rougier P., Adenis A., Ducreux M., de Forni M., Bonneterre J., Dembak M., et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer 2000; 36(8)1016–1025
   PubMed Web of Science ®Google Scholar
• Ueno H., Okusaka T., Funakoshi A., Ishii H., Yamao K., Ishikawa O., et al. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2007; 59(4)447–454
   PubMed Web of Science ®Google Scholar
• Pei X. H., Nakanishi Y., Takayama K., Bai F., Kawasaki M., Tsuruta N., et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 1997; 8(3)231–237
   PubMed Web of Science ®Google Scholar
• Chou T. C., Motzer R. J., Tong Y., Bosl G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 1994; 86(20)1517–1524
   PubMed Web of Science ®Google Scholar
• Docetaxel in combination with irinotecan: Prediction of clinical maximum tolerated dose. Proc Am Soc Clin Oncol 1997
   Google Scholar
• Adjei A. A., Klein C. E., Kastrissios H., Goldberg R. M., Alberts S. R., Pitot H. C., , Phase I, et al. and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J. Clin. Oncol. 2000; 18(5)1116–1123
   PubMed Web of Science ®Google Scholar
• Couteau C., Risse M. L., Ducreux M., Lefresne-Soulas F., Riva A., Lebecq A., , Phase I, et al. and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J. Clin. Oncol. 2000; 18(20)3545–3552
   PubMed Web of Science ®Google Scholar
• Masuda N., Negoro S., Kudoh S., Sugiura T., Nakagawa K., Saka H., , Phase I, et al. and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J. Clin. Oncol. 2000; 18(16)2996–3003
   PubMed Web of Science ®Google Scholar
• Oettle H., Arnold D., Esser M., Huhn D., Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11(8)635–638
   PubMed Web of Science ®Google Scholar
• Ulrich-Pur H., Raderer M., Verena Kornek G., Schull B., Schmid K., Haider K., et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br. J. Cancer 2003; 88(8)1180–1184
   PubMed Web of Science ®Google Scholar
• Tsavaris N., Kosmas C., Skopelitis H., Gouveris P., Kopterides P., Loukeris D., et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest. New Drugs 2005; 23(4)369–375
   PubMed Web of Science ®Google Scholar
• Oettle H., Pelzer U., Stieler J., Hilbig A., Roll L., Schwaner I., et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] plus best supportive careversus best supportive care alone in second-line therapy ofgemcitabine-refractory advanced pancreatic cancer (CONKO 003). (abstract 4031. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; 23, (16S)
   Google Scholar
• Burris H. A., 3rd, Rivkin S., Reynolds R., Harris J., Wax A., Gerstein H., , Phase I I, et al. trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005; 10(3)183–190
   PubMed Web of Science ®Google Scholar
• Boeck S., Weigang-Kohler K., Fuchs M., Kettner E., Quietzsch D., Trojan J., et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann. Oncol. 2007
   Google Scholar
• Blaszkowsky L. S., Kulke K. H., Ryan D. P., Clark J. W., Meyerhardt J., Zhu A. X., et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer (abstract 4099). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; 23, (16S (June 1 Supplement))
   Google Scholar